Compare GameStop Corp. (GME) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

GME trades at $27.22, down slightly by 0.04% on the day. The stock shows strong technical momentum with bullish moving averages and positive price action near resistance at $28. Fundamentally, the company reported net income of $131.3 million in 2025 with improving profit margins of 25.16%, though revenue declined to $3.82 billion. Recent insider buying by CEO Ryan Cohen and directors has driven positive sentiment, with multiple purchases totaling over $26 million in September 2026.

GME presents a mixed outlook with strong insider confidence but challenging fundamentals. The investment opportunity lies in continued operational turnaround and potential strategic moves, while risks include revenue declines, competitive pressures in retail gaming, and the stock's meme stock volatility. Analyst consensus remains cautious with only 16.7% buy ratings versus 27.8% sells.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.